Safety and efficacy of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2), ± cemiplimab in patients with advanced solid tumors from a phase 1 study. Phase 1b dose ...
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases ...
Real-world evidence for enfortumab vedotin (EV) in metastatic urothelial carcinoma (mUC): a multi-centred observational study in a publicly funded Canadian system. This is an ASCO Meeting Abstract ...
PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and ...
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 ...
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss ...
Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...
MADRID — Amycretin, a dual pathway, oral weight loss drug, led to up to 13% body weight loss in participants with overweight or obesity according to phase 1, first-in-human study data presented at the ...
Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results